Sign inJoin waitlistJoin the waitlist

Benjamin Korman

Associate Professor - Department of Medicine, Allergy/Immunology and Rheumatology · URochester Medicine

Credentials: · · · ·

History

URochester Medicine
Present

McGaw Medical Center of Northwestern University
2012–2014
McGaw Medical Center of Northwestern University
2010–2012
McGaw Medical Center of Northwestern University
2009–2010
Ohio State University College of Medicine
2009

Research

An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist
New England Journal of Medicine · 2009 · 702 citations
Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease
Nature Genetics · 2010 · 533 citations
Common variants at CD40 and other loci confer risk of rheumatoid arthritis
Systematic review or meta-analysis · Nature Genetics · 2008 · 448 citations

John Varga
19 papers
Christopher Ritchlin
8 papers
Lindsey Criswell
6 papers
Monique Hinchcliff
6 papers
PG
Peter Gregersen
5 papers
WT
Warren Tourtellotte
5 papers
Howard Kenney
4 papers · 2 as a resident
Ami Shah
3 papers
Avram Goldberg
3 papers
Chris Derk
3 papers
Dinesh Khanna
3 papers
Elana Bernstein
3 papers

Grants

Role of the CD47 Pathway in Rheumatoid Arthritis Pathogenesis and Treatment
National Institute of Arthritis and Musculoskeletal and Skin Diseases · R01
Contact PI · $2.4M · University of Rochester
2022–2027
Role of the Alternative Complement Cascade in Connective Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases · R03
Contact PI · $151.7K · University of Rochester
2020–2023
Contribution of Adipocytes and Adipose Secreted Factors to Fibrosis in Systemic Sclerosis
National Institute of Arthritis and Musculoskeletal and Skin Diseases · K08
Contact PI · $787K · University of Rochester
2016–2021
PPAR-Gamma's Role in Aberrant Adipogenesis and Fibrosis in Systemic Sclerosis
National Institute of Arthritis and Musculoskeletal and Skin Diseases · F32
Contact PI · $70.1K · Northwestern University
2013–2015

Clinical trials

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Site PI · Recruiting · Phase 2, Phase 3
Cabaletta Bio
2024–2029